Including Oral-Only ESRD Drugs In Payment Bundle Could Harm Access: GAO

The inclusion of oral-only end-stage renal disease drugs in the Medicare prospective payment system beginning in 2014 could have a negative effect on access to these drugs if facilities consider bundled reimbursement to be inadequate to cover their cost, according to an analysis by the Government Accountability Office.